Managing IP interviewed Mundipharma’s chief international IP counsel Neil Trueman, who was featured in this year’s Corporate IP Stars publication.
In the interview, Trueman explained the challenges faced by biosimilar manufacturers. He said “the hardest thing is looking ahead” and “[t]he upfront costs to develop a biosimilar are so much higher than a simple molecule”.
He talked about the regulatory and patent protection landscape in Europe and the US as well as patent disputes. On litigation, he said: “Sometimes you don’t win, but that is a risk of litigation, and everybody gets angry that they have to pay out. It’s important to remember the glorious wins you had at the time, even if the ruling gets overturned in the future.”
At the end of the interview, Trueman mentioned two areas of interest for Mundipharma.
Read the full interview here.